Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
DOI
PMC
 |
|
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Scientific and medical evidence informing expansion of hepatitis B treatment guidelines.
Lancet Gastroenterol. Hepatol. 10, 941-951 (2025)
Chronic hepatitis B treatment relies on nucleoside or nucleotide analogue drugs that suppress hepatitis B virus (HBV) replication, normalise liver enzymes, and slow disease progression with excellent safety profiles. Treatment is not curative, and patients remain at risk of cirrhosis and hepatocellular carcinoma. Treatment guidelines have generally restricted antiviral therapy to individuals with high HBV DNA and elevated ALT or hepatic fibrosis, often requiring longitudinal testing that can be scarcely available in resource-limited settings. Consequently, fewer than 3% of people living with HBV infection are receiving antiviral therapy. Guidelines from China and WHO recently broadened access criteria to antiviral therapy, but there are people who fall outside these guidelines who could still benefit from treatment initiation. The pathological processes induced by HBV infection are still active in these patients. We present the benefits and risks of expanding treatment eligibility. We believe that the benefits of reduced hepatic damage and carcinogenic stimuli greatly outweigh the risks.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Closed Circular Dna; Regulatory T-cells; Immune-tolerant; Hepatocellular-carcinoma; Antiviral Therapy; Natural-history; Liver; Infection; Risk; Interferon
ISSN (print) / ISBN
2468-1253
e-ISSN
2468-1253
Zeitschrift
The lancet : Gastroenterology & Hepatology
Quellenangaben
Band: 10,
Heft: 10,
Seiten: 941-951
Verlag
Elsevier
Verlagsort
London
Institut(e)
Institute of Virology (VIRO)